- microRNA in Denmark, BRIC, Cph. University, Denmark
- European Association for the Study of the Liver, Copenhagen
- AACR, Annual meeting.
- 15th Annual Scandinavian Atherosclerosis Conference
- Meeting Medicon Valley arranged by Medicon Valley Alliance, Cph.
- DxRx Summit, Boston, USA
- Danish Biotech Annual Meeting
- Tides, Las Vegas, USA
- BIO, Vancouver, USA
- microRNA Symposium 2009, Vienna.
- DDD Meeting Japan
- SMI 4th conference on RNAi, miRNA and siRNA
- XV International Symposium on Atherosclerosis
- 4th Nucleic Acid Chemical Biology (NACB) Symposium, Odense
Santaris Pharma is represented in the Advisory Board of the Keystone
Guidance for 2009
Santaris Pharma guidance for the year ending 31 December 2009 is a loss
after tax in the range of DKK 115 - 125 million.
Flemming Ornskov Soren Tulstrup
Chairman of the Board President and CEO
The Financial Statements in this Interim Report are presented in
accordance with IAS 34 as adopted by the EU and additional Danish disclosure
requirements for Interim Reports of listed companies. The accounting policies
are consistent with those applied in the Annual Report for 2008. The Interim
Report is un-audited and un-reviewed.
The Income Statement, the Balance Sheet, the Statement of change in
Equity, the Cash Flow Statement and the Cap table are presented below.
Income Statement (1 January - 30 June 2009)
The loss after tax realised in the 2nd quarter of 2008 was 21,6m (2,9m
EUR) compared to 29,8m DKK (4,0m EUR) in 2008. The accumulated loss after tax
for the first half of 2009 was 34,5m DKK (4,6m EUR) compared to 65,6m DKK
(8,8m EUR) in 2008.
The Revenues for the 2nd quarter 2009 amounted to 12,6m DKK (1,7m EUR)
compared to 23,Page: 1 2 3 4 5 6 7 8 9 Related biology technology :1
. Santaris Pharma to Present at 10th Annual Biotechnology Industry Organisation CEO & Investor Conference - February 11th, 20082
. Santaris Pharma Delivers Six LNA-Based RNA Inhibitors to Enzon Pharmaceuticals Ahead of Schedule3
. Santaris Pharma Director Appointed Adjunct Professor in RNA Biology at the University of Aalborg, Denmark4
. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.5
. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory6
. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes7
. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results8
. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court9
. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results10
. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML11
. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007